Johnson & Johnson $JNJ Stock Sold by Parr Mcknight Wealth Management Group LLC

Parr Mcknight Wealth Management Group LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 4.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,036 shares of the company’s stock after selling 2,391 shares during the quarter. Johnson & Johnson comprises 1.6% of Parr Mcknight Wealth Management Group LLC’s investment portfolio, making the stock its 12th largest holding. Parr Mcknight Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $13,247,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. CKW Financial Group raised its holdings in shares of Johnson & Johnson by 0.9% during the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company’s stock valued at $1,104,000 after purchasing an additional 37 shares in the last quarter. Silver Coast Investments LLC boosted its holdings in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV increased its position in Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after buying an additional 39 shares during the last quarter. Triumph Capital Management increased its position in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after buying an additional 39 shares during the last quarter. Finally, Kwmg LLC raised its holdings in Johnson & Johnson by 1.7% during the third quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 3.9%

Shares of JNJ opened at $276.62 on Thursday. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $665.92 billion, a price-to-earnings ratio of 41.91, a P/E/G ratio of 2.63 and a beta of 0.22. The stock’s 50-day moving average price is $265.67 and its 200 day moving average price is $247.74.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the firm earned $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by corporate insiders.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Wall Street analysts remain moderately bullish on J&J’s prospects, according to a review of analyst views. Read article
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase that increased all 60 of the fund’s holdings. This indicates fund buying, but the report does not specify J&J’s allocation or suggest a company-specific investment view. Read article
• Neutral Sentiment: Smith+Nephew cut its outlook and confirmed failed merger discussions with J&J’s orthopedics unit. The talks’ failure removes a potential transaction, but the report does not detail any direct financial impact on J&J. Read article
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The announcement could create negative legal overhang, although it does not provide details about the claims or establish wrongdoing. Read article

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. Bank of America reissued a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.